Joyce A. Lonergan to Head SR One
FOR IMMEDIATE RELEASEMedia Contact: Rick Koenig(610) 270-5546
PHILADELPHIA, PA, February 8, 2007 -- Joyce A. Lonergan has been appointed Managing Partner and President, SR One Ltd, GSK’s independent healthcare venture capital fund, effective immediately.
Lonergan succeeds Adrian Rawcliffe, who was recently named Senior Vice President, Worldwide Business Development, at GSK. Lonergan has been with SR One since 2005.
“Joyce brings a wealth of experience to this role,” said Moncef Slaoui, Chairman, GSK Research & Development. “Her capabilities and leadership complement the team and positions SR One to continue its strategic investment mission."
Lonergan brings over 20 years of experience in healthcare to this position, with roles in corporate development, investor relations, corporate communications, venture capital and Wall Street research at Chiron, Cowen & Company and Caxton Healthcare Venture Management. She serves on the board of Locus Pharmaceuticals and Novalar Pharmaceuticals., Inc. and is an observer on the board of Hypnion, MicroMass Communications, Inc., Rib-X Pharmaceuticals, and Zelos Therapeutics, Inc.
She holds a BS in biology from Emmanuel College and an MBA from Simmons College Graduate School of Management.
SR One is GSK's independent healthcare venture fund. The Fund's mission is to invest globally in emerging biotech companies that are focused on drug discovery, delivery or development and have the potential to make products that will offer a dramatic benefit to patients. SR One is committed to making investments that can provide attractive returns and significant strategic value.
Since its founding in 1985, SR One has invested more than $500 million in biotechnology, and the portfolio comprises more than 30 private and public companies in the US and Europe. The SR One team includes six investment professionals based in the US and Europe and has experience that spans venture-capital investing, business development, Wall Street, pharmaceutical R&D, medical practice, and business start-ups. For more information please visit www.srone.com.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. # # #
2008 SR One Ltd